Tag Archives: Matt Phipps

Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX), Minerva Neurosciences (NASDAQ: NERV) and Atea Pharmaceuticals (NASDAQ: AVIR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dynavax (DVAX – Research Report), Minerva Neurosciences (NERV – Research Report) and Atea Pharmaceuticals (AVIR – Research Report). Minerva Neurosciences (NERV) William Blair

Amgen (AMGN) Receives a Hold from William Blair

In a report released yesterday, Matt Phipps from William Blair maintained a Hold rating on Amgen (AMGN – Research Report). The company’s shares closed last Friday at $217.68, close to its 52-week low of $210.28. According to TipRanks.com, Phipps is

William Blair Thinks Phasebio Pharmaceuticals’ Stock is Going to Recover

In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report). The company’s shares closed last Friday at $2.90, close to its 52-week low of $2.60. According to TipRanks.com, Phipps

Dynavax (DVAX) Gets a Buy Rating from William Blair

In a report issued on September 13, Matt Phipps from William Blair reiterated a Buy rating on Dynavax (DVAX – Research Report). The company’s shares closed last Friday at $14.83. According to TipRanks.com, Phipps is a 4-star analyst with an

Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (NASDAQ: PIRS) and FibroGen (NASDAQ: FGEN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pieris Pharmaceuticals (PIRS – Research Report) and FibroGen (FGEN – Research Report). Pieris Pharmaceuticals (PIRS) William Blair analyst Matt Phipps maintained a Buy

Analysts’ Top Healthcare Picks: Incyte (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Incyte (INCY – Research Report) with bullish sentiments. Incyte (INCY) In a report issued on June 11, Matt Phipps from William